Cartier Flora, Indersie Emilie, Lesjean Sarah, Charpentier Justine, Hooks Katarzyna B, Ghousein Amani, Desplat Angélique, Dugot-Senant Nathalie, Trézéguet Véronique, Sagliocco Francis, Hagedorn Martin, Grosset Christophe F
University of Bordeaux, Inserm, Groupe de Recherche pour l'Etude du Foie, GREF, U1053, F-33076 Bordeaux, France.
University of Bordeaux, Inserm, Biothérapies des Maladies Génétiques Inflammatoires et Cancers, BMGIC, U1035, F-33076 Bordeaux, France.
Oncotarget. 2017 Jun 20;8(25):41211-41226. doi: 10.18632/oncotarget.17162.
Glypican-3 (GPC3) is an oncogene, frequently upregulated in liver malignancies such as hepatocellular carcinoma (HCC) and hepatoblastoma and constitutes a potential molecular target for therapy in liver cancer. Using a functional screening system, we identified 10 new microRNAs controlling GPC3 expression in malignant liver cells, five of them e.g. miR-4510, miR-203a-3p, miR-548aa, miR-376b-3p and miR-548v reduce GPC3 expression. These 5 microRNAs were significantly downregulated in tumoral compared to non-tumoral liver and inhibited tumor cell proliferation. Interestingly, miR-4510 inversely correlated with GPC3 mRNA and protein in HCC samples. This microRNA also induced apoptosis of hepatoma cells and blocked tumor growth in vivo in the chick chorioallantoic membrane model. We further show that the tumor suppressive effect of miR-4510 is mediated through direct targeting of GPC3 mRNA and inactivation of Wnt/β-catenin transcriptional activity and signaling pathway. Moreover, miR-4510 up-regulated the expression of several tumor suppressor genes while reducing the expression of other pro-oncogenes. In summary, we uncovered several new microRNAs targeting the oncogenic functions of GPC3. We provided strong molecular, cellular and in vivo evidences for the tumor suppressive activities of miR-4510 bringing to the fore the potential value of this microRNA in HCC therapy.
磷脂酰肌醇蛋白聚糖-3(GPC3)是一种癌基因,在肝细胞癌(HCC)和肝母细胞瘤等肝脏恶性肿瘤中经常上调,是肝癌治疗的潜在分子靶点。利用功能筛选系统,我们鉴定出10种控制恶性肝细胞中GPC3表达的新微小RNA,其中5种,如miR-4510、miR-203a-3p、miR-548aa、miR-376b-3p和miR-548v可降低GPC3表达。与非肿瘤肝脏相比,这5种微小RNA在肿瘤中显著下调,并抑制肿瘤细胞增殖。有趣的是,在HCC样本中,miR-4510与GPC3 mRNA和蛋白呈负相关。这种微小RNA还可诱导肝癌细胞凋亡,并在鸡胚绒毛尿囊膜模型中阻断体内肿瘤生长。我们进一步表明,miR-4510的肿瘤抑制作用是通过直接靶向GPC3 mRNA以及使Wnt/β-连环蛋白转录活性和信号通路失活来介导的。此外,miR-4510上调了几种肿瘤抑制基因的表达,同时降低了其他原癌基因的表达。总之,我们发现了几种靶向GPC3致癌功能的新微小RNA。我们为miR-4510的肿瘤抑制活性提供了有力的分子、细胞和体内证据,凸显了这种微小RNA在HCC治疗中的潜在价值。